Aspirin and dipyridamole and Leustatin injection
Determining the interaction of Aspirin and dipyridamole and Leustatin injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown. MANAGEMENT: Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:GENERALLY AVOID: Oral bioavailability and systemic exposure of cladribine may be increased by potent inhibitors of breast cancer resistance protein (BCRP) while intracellular distribution and renal elimination of cladribine may be altered by potent inhibitors of equilibrative nucleoside transporter 1 (ENT1) and concentrative nucleoside transporter 3 (CNT3). The mechanism involves inhibition of ENT1, CNT3, and/or BCRP as cladribine is a substrate of each of these transporter systems. The clinical relevance remains unknown.
MANAGEMENT: Coadministration of potent ENT1, CNT3, or BCRP transporter inhibitors should be avoided during the 4 to 5-day oral cladribine treatment cycles. If coadministration is required, consider concomitant alternatives that exhibit no or minimal inhibition of ENT1, CNT3, or BCRP. If this is not possible, dose reduction to the minimum mandatory dose, separation in the timing of administration, and careful patient monitoring is recommended.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: aspirin / dipyridamole
Brand name: Aggrenox
Synonyms: Aspirin and Dipyridamole
Generic Name: cladribine
Brand name: Leustatin, Mavenclad
Synonyms: Leustatin (injection), Leustatin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aspirin and dipyridamole-Leva Set
- Aspirin and dipyridamole-Levacet
- Aspirin and dipyridamole-Levalbuterol
- Aspirin and dipyridamole-Levalbuterol HFA Aerosol
- Aspirin and dipyridamole-Levalbuterol inhalation
- Aspirin and dipyridamole-Levalbuterol Inhalation Aerosol
- Leustatin injection-Aspirin and Dipyridamole Capsules
- Leustatin injection-Aspirin and omeprazole
- Leustatin injection-Aspirin and Omeprazole Tablets
- Leustatin injection-Aspirin and oxycodone
- Leustatin injection-Aspirin Chewable Tablets
- Leustatin injection-Aspirin Enteric-Coated and Buffered Tablets